-+ 0.00%
-+ 0.00%
-+ 0.00%

Cumberland sells branded drug portfolio to Apotex for $100 million cash

PUBT·04/23/2026 13:02:53
Listen to the news
Cumberland sells branded drug portfolio to Apotex for $100 million cash
  • Apotex agreed to acquire Cumberland branded U.S. pharmaceuticals for cash consideration of USD 100 million.
  • Deal integrates Cumberland commercial business with Apotex to build a U.S. specialty-medicines platform.
  • Cumberland will retain pipeline candidates, including ifetroban programs in Duchenne muscular dystrophy cardiomyopathy, systemic sclerosis, and idiopathic pulmonary fibrosis.
  • Company will also keep its majority ownership stake in Cumberland Emerging Technologies.
  • Transaction requires authorization and approval by Cumberland shareholders.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL42107) on April 23, 2026, and is solely responsible for the information contained therein.